The Pharmacological Effects of Lutein and Zeaxanthin on Visual Disorders and Cognition Diseases

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Apr 21

PMID 28425969

Citations 48

Authors

Yu-Ping Jia

Lei Sun

He-Shui Yu

Li-Peng Liang

Wei Li

Hui Ding

Xin-Bo Song

Li-Juan Zhang

Affiliations

Soon will be listed here.

Abstract

Lutein (L) and zeaxanthin (Z) are dietary carotenoids derived from dark green leafy vegetables, orange and yellow fruits that form the macular pigment of the human eyes. It was hypothesized that they protect against visual disorders and cognition diseases, such as age-related macular degeneration (AMD), age-related cataract (ARC), cognition diseases, ischemic/hypoxia induced retinopathy, light damage of the retina, retinitis pigmentosa, retinal detachment, uveitis and diabetic retinopathy. The mechanism by which they are involved in the prevention of eye diseases may be due their physical blue light filtration properties and local antioxidant activity. In addition to their protective roles against light-induced oxidative damage, there are increasing evidences that L and Z may also improve normal ocular function by enhancing contrast sensitivity and by reducing glare disability. Surveys about L and Z supplementation have indicated that moderate intakes of L and Z are associated with decreased AMD risk and less visual impairment. Furthermore, this review discusses the appropriate consumption quantities, the consumption safety of L, side effects and future research directions.

Citing Articles

BlingLife-Marigold Extract Alleviates Blue Light-Induced Retinal Mitochondria Oxidative Stress and Senescence by Activating NRF2/HO-1 Signaling.

Zhou Z, Li S, Yang Q, Zheng P, Xie K J Microbiol Biotechnol. 2025; 35:e2411037.

PMID: 40016150 PMC: 11896799. DOI: 10.4014/jmb.2411.11037.

Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer's Disease.

Flieger J, Forma A, Flieger W, Flieger M, Gawlik P, Dzierzynski E Int J Mol Sci. 2024; 25(16).

PMID: 39201668 PMC: 11354426. DOI: 10.3390/ijms25168982.

Bioactivity and Bioavailability of Carotenoids Applied in Human Health: Technological Advances and Innovation.

Bas T Int J Mol Sci. 2024; 25(14).

PMID: 39062844 PMC: 11277215. DOI: 10.3390/ijms25147603.

The Role of Reactive Oxygen Species in Age-Related Macular Degeneration: A Comprehensive Review of Antioxidant Therapies.

Kulbay M, Wu K, Nirwal G, Belanger P, Tran S Biomedicines. 2024; 12(7).

PMID: 39062152 PMC: 11274723. DOI: 10.3390/biomedicines12071579.

The low and high doses administration of lutein improves memory and synaptic plasticity impairment through different mechanisms in a rat model of vascular dementia.

Asadi Nejad H, Yousefi Nejad A, Akbari S, Naseh M, Shid Moosavi S, Haghani M PLoS One. 2024; 19(5):e0302850.

PMID: 38748711 PMC: 11095768. DOI: 10.1371/journal.pone.0302850.

References

Markesbery W . The role of oxidative stress in Alzheimer disease. Arch Neurol. 1999; 56(12):1449-52. DOI: 10.1001/archneur.56.12.1449. View

Chew E, Clemons T, Agron E, Sperduto R, SanGiovanni J, Davis M . Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014; 132(3):272-7. PMC: 11551520. DOI: 10.1001/jamaophthalmol.2013.6636. View

Maharshak N, Shapiro J, Trau H . Carotenoderma--a review of the current literature. Int J Dermatol. 2003; 42(3):178-81. DOI: 10.1046/j.1365-4362.2003.01657.x. View

Johnson E, Vishwanathan R, Johnson M, Hausman D, Davey A, Scott T . Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res. 2013; 2013:951786. PMC: 3690640. DOI: 10.1155/2013/951786. View

Vishwanathan R, Kuchan M, Sen S, Johnson E . Lutein and preterm infants with decreased concentrations of brain carotenoids. J Pediatr Gastroenterol Nutr. 2014; 59(5):659-65. DOI: 10.1097/MPG.0000000000000389. View

Xing K, Lou M . Effect of age on the thioltransferase (glutaredoxin) and thioredoxin systems in the human lens. Invest Ophthalmol Vis Sci. 2010; 51(12):6598-604. PMC: 3055771. DOI: 10.1167/iovs.10-5672. View

GASS J . Müller cell cone, an overlooked part of the anatomy of the fovea centralis: hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. Arch Ophthalmol. 1999; 117(6):821-3. DOI: 10.1001/archopht.117.6.821. View

Nolan J, Loskutova E, Howard A, Moran R, Mulcahy R, Stack J . Macular pigment, visual function, and macular disease among subjects with Alzheimer's disease: an exploratory study. J Alzheimers Dis. 2014; 42(4):1191-202. DOI: 10.3233/JAD-140507. View

Devore E, Grodstein F, van Rooij F, Hofman A, Stampfer M, Witteman J . Dietary antioxidants and long-term risk of dementia. Arch Neurol. 2010; 67(7):819-25. PMC: 2923546. DOI: 10.1001/archneurol.2010.144. View

10.

Cangemi F . TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol. 2007; 7:3. PMC: 1831760. DOI: 10.1186/1471-2415-7-3. View

11.

Subczynski W, Wisniewska A, Widomska J . Location of macular xanthophylls in the most vulnerable regions of photoreceptor outer-segment membranes. Arch Biochem Biophys. 2010; 504(1):61-6. PMC: 2957566. DOI: 10.1016/j.abb.2010.05.015. View

12.

Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S . Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology. 2007; 115(2):324-333.e2. DOI: 10.1016/j.ophtha.2007.05.029. View

13.

Fan X, Zhang J, Theves M, Strauch C, Nemet I, Liu X . Mechanism of lysine oxidation in human lens crystallins during aging and in diabetes. J Biol Chem. 2009; 284(50):34618-27. PMC: 2787324. DOI: 10.1074/jbc.M109.032094. View

14.

Alves-Rodrigues A, Shao A . The science behind lutein. Toxicol Lett. 2004; 150(1):57-83. DOI: 10.1016/j.toxlet.2003.10.031. View

15.

Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D . Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004; 75(4):216-30. DOI: 10.1016/s1529-1839(04)70049-4. View

16.

Miller J . Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2012; 155(1):1-35.e13. DOI: 10.1016/j.ajo.2012.10.018. View

17.

Kelm M, Flanagan V, Pawlosky R, Novotny J, Clevidence B, Britz S . Quantitative determination of 13C-labeled and endogenous beta-carotene, lutein, and vitamin A in human plasma. Lipids. 2002; 36(11):1277-82. DOI: 10.1007/s11745-001-0842-1. View

18.

Sommerburg O, Siems W, Hurst J, Lewis J, Kliger D, Van Kuijk F . Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res. 1999; 19(6):491-5. DOI: 10.1076/ceyr.19.6.491.5276. View

19.

Renzi L, Hammond B . The effect of macular pigment on heterochromatic luminance contrast. Exp Eye Res. 2010; 91(6):896-900. DOI: 10.1016/j.exer.2010.09.015. View

20.

Karppi J, Laukkanen J, Kurl S . Plasma lutein and zeaxanthin and the risk of age-related nuclear cataract among the elderly Finnish population. Br J Nutr. 2011; 108(1):148-54. DOI: 10.1017/S0007114511005332. View